LexisNexis® Legal Newsroom
Generic Pharma Leverages PTAB

IPRs and Drug Litigation Since Post Grant Review (PGR) is designed to challenge patents on 112 and 101 grounds not available in Inter Partes Review (IPR), it is often assumed that Bio/Pharma is somewhat unconcerned with the growing trend to challenge patents in IPR at the PTAB . Today, my partner...